Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Nvidia’s RTX 30 Launch Is a Positive Game-Changer

By Chris Lau, InvestorPlace Contributor

NVDA stock will benefit from the game-changing refresh of the GeForce, with the RTX 30 product release, despite the recent pull-back.

Plug Power Is in the Driver’s Seat as Hydrogen Use Grows

By Chris Lau, InvestorPlace Contributor

Mega deals for Plug Power from companies like Walmart and Home Depot are set to lift PLUG stock further.

What Happens Next After Workhorse’s Spectacular Run-up

By Chris Lau, InvestorPlace Contributor

Bears are wrong in their big bet against WKHS stock, as a huge influx in Ryder orders is set to boost revenue.

When It Comes to Novavax Stock, It’s All About Clinical Results

By Chris Lau, InvestorPlace Contributor

Novavax had a good run in the last few months and after the August drop, investors will look forward to the clinical study numbers

Why the New F-150 Could Move the Needle for Ford

By Chris Lau, InvestorPlace Contributor

F stock will likely continue to rebound as the company is preparing to release multiple promising vehicles.

7 Cheap Stocks for the Cash-Strapped Investor

By Chris Lau, InvestorPlace Contributor

Investors have many cheap stocks to buy, using widely-followed metrics or by looking at those lacking institutional interest.

Why CureVac Might Soar From Here

By Chris Lau, InvestorPlace Contributor

The coronavirus vaccine play is crowded and CureVac stock needs to win more deals to get noticed

Why Delta Is the Strongest Airline

By Chris Lau, InvestorPlace Contributor

DAL stock could provide double-digit percentage returns in the near-term as long as investors do not hold the stock for too long.

What Investors Should Do After Nio Diluted Shares

By Chris Lau, InvestorPlace Contributor

Nio stock looks like a very cheap electric vehicle trade compared to Tesla but beware of near-term selling pressures ahead.

Why Zoom Communications Is Still a Sizzling Hot Trade

By Chris Lau, InvestorPlace Contributor

A huge spike in the number of people staying home has boosted ZM stock, and the trend should push the shares even higher

Load More